Codexis Company Profile (NASDAQ:CDXS)

About Codexis

Codexis logoCodexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Industry, Sector and Symbol:
  • Sector: Industrial Products
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CDXS
  • CUSIP: 19200510
Key Metrics:
  • Previous Close: $4.15
  • 50 Day Moving Average: $4.68
  • 200 Day Moving Average: $4.54
  • 52-Week Range: $2.93 - $5.28
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -18.41
  • P/E Growth: -1.49
  • Market Cap: $169.00M
  • Outstanding Shares: 41,220,000
  • Beta: -1
Profitability:
  • Net Margins: -10.60%
  • Return on Equity: -5.25%
  • Return on Assets: -2.69%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 2.57%
  • Quick Ratio: 2.48%
Additional Links:
Companies Related to Codexis:

Analyst Ratings

Consensus Ratings for Codexis (NASDAQ:CDXS) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.92 (46.09% upside)

Analysts' Ratings History for Codexis (NASDAQ:CDXS)
Show:
DateFirmActionRatingPrice TargetDetails
1/26/2017First AnalysisDowngradeOverweight -> Equal Weight$5.50View Rating Details
1/4/2017Ladenburg Thalmann Financial ServicesUpgradeNeutral -> Buy$6.25View Rating Details
6/1/2016HC WainwrightInitiated CoverageBuy$6.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Codexis (NASDAQ:CDXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017        
11/8/2016Q3($0.14)$0.09$7.41 million$14.90 millionViewListenView Earnings Details
8/9/2016Q216$0.03$0.12$15.10 million$16.00 millionViewListenView Earnings Details
5/9/2016Q1($0.15)($0.11)$7.49 million$8.00 millionViewListenView Earnings Details
3/3/2016Q4($0.04)$0.02$11.63 million$11.60 millionViewN/AView Earnings Details
11/4/2015Q315($0.11)$0.19$8.85 million$17.40 millionViewListenView Earnings Details
8/11/2015Q215($0.14)($0.14)$7.34 million$6.02 millionViewListenView Earnings Details
5/7/2015Q115($0.12)($0.14)$8.00 million$6.80 millionViewListenView Earnings Details
3/3/2015Q414$0.01$0.07$13.30 million$14.20 millionViewListenView Earnings Details
11/4/2014Q314($0.06)($0.05)$9.00 million$7.47 millionViewListenView Earnings Details
8/6/2014Q214($0.15)($0.22)$8.50 million$6.60 millionViewListenView Earnings Details
5/7/2014Q114($0.10)($0.17)$10.00 million$7.10 millionViewListenView Earnings Details
3/11/2014Q413($0.21)($0.26)$10.00 million$9.50 millionViewListenView Earnings Details
11/12/2013Q313($0.31)($0.24)$8.50 million$3.90 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.28)($0.33)$9.00 million$6.97 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.36)($0.25)$7.63 million$11.48 millionViewListenView Earnings Details
2/27/2013Q4 2012($0.34)($0.41)$9.33 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.15)($0.06)$25.88 million$26.34 millionViewN/AView Earnings Details
8/9/2012($0.18)($0.15)ViewN/AView Earnings Details
5/10/2012($0.15)($0.21)ViewN/AView Earnings Details
2/7/2012($0.11)($0.15)ViewN/AView Earnings Details
11/1/2011($0.08)($0.08)ViewN/AView Earnings Details
7/28/2011($0.10)($0.14)ViewN/AView Earnings Details
5/5/2011($0.07)($0.10)ViewN/AView Earnings Details
2/3/2011($0.06)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Codexis (NASDAQ:CDXS)
Current Year EPS Consensus Estimate: $-0.19 EPS
Next Year EPS Consensus Estimate: $-0.22 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.16)($0.08)($0.12)
Q2 20162$0.02$0.06$0.04
Q3 20162($0.13)($0.08)($0.11)
Q4 20162($0.07)$0.06($0.01)
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.12)($0.12)($0.12)
Q3 20171($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Codexis (NASDAQ:CDXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Codexis (NASDAQ:CDXS)
Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 57.65%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2016Patrick Y YangDirectorBuy10,000$4.83$48,300.00View SEC Filing  
9/8/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell111,600$4.25$474,300.00View SEC Filing  
8/29/2016Dennis P WolfDirectorSell18,000$4.22$75,960.00View SEC Filing  
8/24/2016Bernard J KelleyDirectorSell12,643$4.26$53,859.18View SEC Filing  
8/16/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell86,894$4.25$369,299.50View SEC Filing  
8/15/2016Vivo Ventures Vii, LlcMajor ShareholderSell50,000$4.27$213,500.00View SEC Filing  
8/4/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell80,000$4.22$337,600.00View SEC Filing  
11/11/2015James LalondeSVPSell9,441$3.52$33,232.32View SEC Filing  
9/11/2015Patrick Y YangDirectorBuy10,000$3.47$34,700.00View SEC Filing  
9/10/2015Bernard J. KelleyDirectorSell5,200$3.45$17,940.00View SEC Filing  
8/24/2015Patrick Y YangDirectorBuy10,000$3.84$38,400.00View SEC Filing  
8/14/2015Patrick Y YangDirectorBuy20,000$3.97$79,400.00View SEC Filing  
6/15/2015Dennis P WolfDirectorSell35,416$4.10$145,205.60View SEC Filing  
11/18/2014Patrick Y YangDirectorBuy20,000$2.35$47,000.00View SEC Filing  
11/17/2014Patrick Y YangDirectorBuy20,000$2.34$46,800.00View SEC Filing  
8/12/2014Patrick Y YangDirectorBuy60,000$2.22$133,200.00View SEC Filing  
3/8/2013John J NicolsCEOBuy27,000$2.42$65,340.00View SEC Filing  
3/7/2013John J NicolsCEOBuy54,000$2.22$119,880.00View SEC Filing  
3/4/2013David D O'tooleCFOBuy10,000$2.02$20,200.00View SEC Filing  
11/12/2012David D O'tooleCFOBuy5,000$2.20$11,000.00View SEC Filing  
9/14/2012David D O'tooleCFOBuy5,000$2.78$13,900.00View SEC Filing  
9/14/2012Douglas T SheehySVPSell3,800$2.76$10,488.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Codexis (NASDAQ:CDXS)
DateHeadline
nasdaq.com logoWhat's in Store for KBR Inc. (KBR) this Earnings Season? (NASDAQ:CDXS)
www.nasdaq.com - February 21 at 2:25 PM
finance.yahoo.com logoQuanta Services (PWR) Q4 Earnings: What's in the Cards? (NASDAQ:CDXS)
finance.yahoo.com - February 16 at 9:02 AM
nasdaq.com logoDeere (DE) Q1 Earnings: A Beat in Store for the Stock? (NASDAQ:CDXS)
www.nasdaq.com - February 13 at 4:49 PM
finance.yahoo.com logoShould Codexis (CDXS) Be On Your Radar Now? (NASDAQ:CDXS)
finance.yahoo.com - January 9 at 5:23 PM
News IconCodexis Inc CDXS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CDXS)
www.bioportfolio.com - January 8 at 4:08 PM
publicnow.com logoCodexis to Offer High-Performance Enzymes for Diagnostics Markets (NASDAQ:CDXS)
www.publicnow.com - January 6 at 4:35 PM
finance.yahoo.com logoCodexis upgraded by Ladenburg Thalmann (NASDAQ:CDXS)
finance.yahoo.com - January 4 at 5:15 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Codexis, EMCORE, Intevac, Organovo Holdings and StarTek (NASDAQ:CDXS)
finance.yahoo.com - January 4 at 5:15 PM
finance.yahoo.com logo5 of the Best Stocks Under $10 for 2017 (NASDAQ:CDXS)
finance.yahoo.com - January 3 at 5:52 PM
capitalcube.com logoETFs with exposure to Codexis, Inc. : December 14, 2016 (NASDAQ:CDXS)
www.capitalcube.com - December 14 at 5:10 PM
marketwatch.com logoCodexis to Commercially Supply Proprietary Enzyme to Tate & Lyle (NASDAQ:CDXS)
www.marketwatch.com - December 6 at 12:02 PM
us.rd.yahoo.com logo7:03 am Codexis appoints Bernard J. Kelley as Chairman, effective November 29 (NASDAQ:CDXS)
us.rd.yahoo.com - December 2 at 4:34 PM
capitalcube.com logoETFs with exposure to Codexis, Inc. : December 2, 2016 (NASDAQ:CDXS)
www.capitalcube.com - December 2 at 4:34 PM
streetinsider.com logoCodexis (CDXS) Appoints New Board Chair (NASDAQ:CDXS)
www.streetinsider.com - December 1 at 4:19 PM
publicnow.com logoCodexis Names Pharmaceutical Industry Veteran Bernard J. Kelley Chairman of the Board (NASDAQ:CDXS)
www.publicnow.com - December 1 at 4:19 PM
News IconCodexis, Inc. CDXS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CDXS)
www.bioportfolio.com - November 23 at 1:10 PM
capitalcube.com logoCodexis, Inc. :CDXS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016 (NASDAQ:CDXS)
www.capitalcube.com - November 23 at 1:10 PM
News IconCodexis, Inc. CDXS Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:CDXS)
www.bioportfolio.com - November 18 at 8:27 PM
finance.yahoo.com logoCODEXIS INC Financials (NASDAQ:CDXS)
finance.yahoo.com - November 17 at 3:20 PM
finance.yahoo.com logoCodexis to Present at the 7th Annual Craig-Hallum Alpha Select Conference (NASDAQ:CDXS)
finance.yahoo.com - November 10 at 12:01 PM
finance.yahoo.com logoEdited Transcript of CDXS earnings conference call or presentation 8-Nov-16 9:30pm GMT (NASDAQ:CDXS)
finance.yahoo.com - November 9 at 4:08 PM
einnews.com logoCodexis Reports Financial Results for the Third Quarter of 2016 (NASDAQ:CDXS)
uspolitics.einnews.com - November 8 at 9:23 PM
sg.finance.yahoo.com logoCodexis beats 3Q profit forecasts (NASDAQ:CDXS)
sg.finance.yahoo.com - November 8 at 9:23 PM
biz.yahoo.com logoQ3 2016 Codexis Inc Earnings Release - After Market Close (NASDAQ:CDXS)
biz.yahoo.com - November 8 at 2:32 PM
News IconCodexis, Inc. To Hold 2016 Third Quarter Conference Call On November 8 (NASDAQ:CDXS)
www.biospace.com - November 2 at 3:49 PM
publicnow.com logoCodexis to Hold 2016 Third Quarter Conference Call on November 8 (NASDAQ:CDXS)
www.publicnow.com - November 1 at 8:15 AM
biz.yahoo.com logoCODEXIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation (NASDAQ:CDXS)
biz.yahoo.com - October 20 at 3:38 PM
News IconBlackstone in the lead to acquire Team Health (NASDAQ:CDXS)
crcconnection.com - October 20 at 8:58 AM
publicnow.com logoMichael Aldridge Joins Codexis as Senior Vice President, Corporate & Strategic Development (NASDAQ:CDXS)
www.publicnow.com - October 17 at 9:00 AM
marketexclusive.com logoCodexis, Inc. (NASDAQ:CDXS) Files An 8-K (NASDAQ:CDXS)
marketexclusive.com - October 7 at 9:03 AM
biz.yahoo.com logoCODEXIS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CDXS)
biz.yahoo.com - October 5 at 4:24 PM
publicnow.com logoCodexis Completes Transfer of CodeEvolver® Technology to Merck (NASDAQ:CDXS)
www.publicnow.com - October 5 at 9:18 AM
capitalcube.com logoETF’s with exposure to Codexis, Inc. : September 29, 2016 (NASDAQ:CDXS)
www.capitalcube.com - September 29 at 4:01 PM
capitalcube.com logoETF’s with exposure to Codexis, Inc. : September 14, 2016 (NASDAQ:CDXS)
www.capitalcube.com - September 14 at 4:09 PM
finance.yahoo.com logoCodexis to Present at September Investment Conferences (NASDAQ:CDXS)
finance.yahoo.com - September 6 at 8:56 AM
finance.yahoo.com logoHow Codexis (CDXS) Stock Stands Out in a Strong Industry (NASDAQ:CDXS)
finance.yahoo.com - August 18 at 12:29 PM
capitalcube.com logoCodexis, Inc. :CDXS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:CDXS)
www.capitalcube.com - August 15 at 4:17 PM
finance.yahoo.com logoEdited Transcript of CDXS earnings conference call or presentation 9-Aug-16 8:30pm GMT (NASDAQ:CDXS)
finance.yahoo.com - August 10 at 3:37 PM
globenewswire.com logoCodexis Reports Financial Results for the Second Quarter of 2016 (NASDAQ:CDXS)
globenewswire.com - August 9 at 9:56 PM
sg.finance.yahoo.com logoCodexis beats 2Q profit forecasts (NASDAQ:CDXS)
sg.finance.yahoo.com - August 9 at 9:56 PM
biz.yahoo.com logoQ2 2016 Codexis Inc Earnings Release - After Market Close (NASDAQ:CDXS)
biz.yahoo.com - August 9 at 12:47 PM
finance.yahoo.com logoIndustrial Stocks' Aug 9 Earnings Preview: LABL, CDXS & More (NASDAQ:CDXS)
finance.yahoo.com - August 8 at 8:56 AM
publicnow.com logoCodexis to Hold 2016 Second Quarter Conference Call on August 9 (NASDAQ:CDXS)
www.publicnow.com - August 2 at 8:55 AM
publicnow.com logoCodexis Completes Obligations Under Research and Development Agreement with Leading Biopharmaceutical Company (NASDAQ:CDXS)
www.publicnow.com - July 28 at 7:08 AM
finance.yahoo.com logo7:01 am Codexis announces the successful completion of its obligations under a collaborative R&D agreement with a 'leading global biopharmaceutical company' (NASDAQ:CDXS)
finance.yahoo.com - July 28 at 7:01 AM
capitalcube.com logoETF’s with exposure to Codexis, Inc. : July 26, 2016 (NASDAQ:CDXS)
www.capitalcube.com - July 26 at 12:44 PM
capitalcube.com logoETF’s with exposure to Codexis, Inc. : July 1, 2016 (NASDAQ:CDXS)
www.capitalcube.com - July 1 at 6:02 PM
biz.yahoo.com logoCODEXIS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:CDXS)
biz.yahoo.com - June 16 at 4:04 PM
publicnow.com logoCodexis to Present at Jefferies 2016 Healthcare Conference (NASDAQ:CDXS)
www.publicnow.com - June 2 at 7:15 AM
biz.yahoo.com logoQ1 2016 Codexis Inc Earnings Release - After Market Close (NASDAQ:CDXS)
biz.yahoo.com - May 9 at 7:07 AM

Social

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Where is Codexis' stock going? Where will Codexis' stock price be in 2017?

3 brokerages have issued 1-year price objectives for Codexis' shares. Their predictions range from $5.50 to $6.25. On average, they expect Codexis' stock price to reach $5.92 in the next twelve months.

When will Codexis announce their earnings?

Codexis is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

Who owns Codexis stock?

Codexis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (12.85%), FMR LLC (4.99%), Baillie Gifford & Co. (2.88%), Opaleye Management Inc. (2.84%), Renaissance Technologies LLC (2.08%) and William Blair Investment Management LLC (1.71%). Company insiders that own Codexis stock include Bernard J Kelley, Dennis P Wolf, James Lalonde, Patrick Y Yang, Ventures Fund Vii LP Vivo and Vivo Ventures Vii, Llc.

Who sold Codexis stock? Who is selling Codexis stock?

Codexis' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Oxford Asset Management, Renaissance Technologies LLC, William Blair Investment Management LLC and Dimensional Fund Advisors LP. Company insiders that have sold Codexis stock in the last year include Bernard J Kelley, Dennis P Wolf, Ventures Fund Vii LP Vivo and Vivo Ventures Vii, Llc.

Who bought Codexis stock? Who is buying Codexis stock?

Codexis' stock was bought by a variety of institutional investors in the last quarter, including Comprehensive Portfolio Management LLC and State Street Corp.

How do I buy Codexis stock?

Shares of Codexis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Codexis stock cost?

One share of Codexis stock can currently be purchased for approximately $4.05.

Codexis (NASDAQ:CDXS) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Earnings History Chart

Earnings by Quarter for Codexis (NASDAQ:CDXS)

Dividend History Chart

Dividend Payments by Quarter for Codexis (NASDAQ:CDXS)

Last Updated on 2/22/2017 by MarketBeat.com Staff